Skip to main content
Journal cover image

Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients.

Publication ,  Journal Article
Shah, NP; Page, C; Green, CL; Gao, M; Cavalier, J; McGarrah, RW; DeWald, TA; Sangvai, D; Patel, MR; Pagidipati, NJ
Published in: Am J Cardiol
January 1, 2023

Guidelines recommend aggressive low-density lipoprotein cholesterol (LDL-C) lowering in patients with atherosclerotic cardiovascular disease (ASCVD). However, the recommended threshold of LDL-C ≤70 mg/dL is often not achieved. We used data from the Duke University Health System electronic health record to characterize patterns of lipid levels and lipid management in patients with ASCVD to estimate the number of clinical events that could be prevented by achieving LDL-C ≤70 mg/dL . A multivariable logistic regression model was developed to predict the 1-year composite of all-cause mortality, myocardial infarction, stroke, or coronary revascularization and was validated through bootstrapping. The number needed to treat to prevent an event was then determined. Among 56,230 patients with ASCVD, the median (quartile 1, quartile 3) age was 68.6 years (59.9, 76.2), 47% were women, and 27% were non-Hispanic Black. LDL-C was >70 mg/dL in 39,566 of patients (70%); these patients were more frequently female (51% vs 36%), non-Hispanic Black (28% vs 23%), and less frequently on statin therapy (67% vs 91%) than those with LDL-C ≤70 mg/dL . A predictive model with reasonable discrimination (c-index 0.77, 95% confidence interval 0.760 to 0.77) and calibration (slope 0.99) determined that if the overall population achieved an LDL-C ≤70 mg/dL, 734 clinical events (455 myocardial infarctions, 186 strokes, and 93 coronary revascularizations) could be prevented in a year. Achieving LDL-C ≤70 mg/dL in patients with ASCVD across a health system could prevent significant clinical events within a single year. In conclusion, this study quantifies the potential benefit of a system-wide effort to achieve guideline-based LDL-C goals.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

January 1, 2023

Volume

186

Start / End Page

91 / 99

Location

United States

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Myocardial Infarction
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Goals
  • Female
  • Cholesterol, LDL
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, N. P., Page, C., Green, C. L., Gao, M., Cavalier, J., McGarrah, R. W., … Pagidipati, N. J. (2023). Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients. Am J Cardiol, 186, 91–99. https://doi.org/10.1016/j.amjcard.2022.10.033
Shah, Nishant P., Courtney Page, Cynthia L. Green, Michael Gao, Joanna Cavalier, Robert W. McGarrah, Tracy A. DeWald, Devdutta Sangvai, Manesh R. Patel, and Neha J. Pagidipati. “Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients.Am J Cardiol 186 (January 1, 2023): 91–99. https://doi.org/10.1016/j.amjcard.2022.10.033.
Shah NP, Page C, Green CL, Gao M, Cavalier J, McGarrah RW, DeWald TA, Sangvai D, Patel MR, Pagidipati NJ. Bending the Cardiovascular Event Curve by Evaluating the Potential Impact of Achieving Low-Density Lipoprotein Cholesterol Goal Across a Large Health System Among Secondary Prevention Patients. Am J Cardiol. 2023 Jan 1;186:91–99.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

January 1, 2023

Volume

186

Start / End Page

91 / 99

Location

United States

Related Subject Headings

  • Stroke
  • Secondary Prevention
  • Myocardial Infarction
  • Male
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Goals
  • Female
  • Cholesterol, LDL
  • Cardiovascular System & Hematology